

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

HMC-1.2

RRID:CVCL_H205

Type: Cell Line

Proper Citation

RRID:CVCL_H205

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_H205

Proper Citation: RRID:CVCL_H205

Description: Cell line HMC-1.2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Mast cell leukemia

Defining Citation: [PMID:11861291](#), [PMID:12519307](#), [PMID:20814942](#), [PMID:25149487](#), [PMID:37025992](#)

Comments: Characteristics: Compound 48/80 which is used to promote mast cell degranulation is toxic to this cell line (DOI=10.57844/arcadia-3207-4695).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HMC-1.2

Synonyms: HMC-1_2, HMC1_2, HMC1.2, HMC-1(560,816), HMC-1-560_816

Cross References: cancercellines:CVCL_H205, Cosmic:819945, Cosmic:1476310, Cosmic:1476422, Cosmic:1498492, GEO:GSM6674137, GEO:GSM6674138, GEO:GSM6674139, Millipore:SCC062, Wikidata:Q54889910

ID: CVCL_H205

Hierarchy: cvcl_0003

Record Creation Time: 20220427T220436+0000

Ratings and Alerts

No rating or validation information has been found for HMC-1.2.

No alerts have been found for HMC-1.2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Leipe A, et al. (2026) Pharmacological modulation of TRPV2 enhances migration and induces Immunoglobulin E (IgE)-independent degranulation of mast cells. *Cell calcium*, 136, 103166.

Grootens J, et al. (2019) Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis. *EBioMedicine*, 43, 150.

Smith BD, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. *Cancer cell*, 35(5), 738.